-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Allogene Therapeutics, which focuses on the development of allogeneic CAR-T therapy, announced that the US FDA has granted its innovative therapy ALLO-316 Fast Track designation
Clear cell renal cell carcinoma is a disease with a significant unmet medical need.
The CAR-T therapy targets CD70, which is highly expressed in renal cell carcinoma and limited in other healthy tissues
▲Allogene's R&D pipeline (Image source: Allogene's official website)
Given that ALLO-316 may address an unmet need in this group of patients, the FDA granted Fast Track designation to the therapy
References:
[1] Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma, Retrieved March 11, 2022, from https:// /03/10/2400941/0/en/Allogene-Therapeutics-Receives-FDA-Fast-Track-Designation-for-its-First-Solid-Tumor-Candidate-ALLO-316-in-the-Treatment-of-Renal -Cell-Carcinoma.
(Original abridged)